- Home
- PRI vs EXEL Comparison
PRI vs EXEL Comparison
Compare PRI & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRI
- EXEL
- Stock Information
- Founded
- PRI 1927
- EXEL 1994
- Country
- PRI United States
- EXEL United States
- Employees
- PRI N/A
- EXEL N/A
- Industry
- PRI Life Insurance
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRI Finance
- EXEL Health Care
- Exchange
- PRI Nasdaq
- EXEL Nasdaq
- Market Cap
- PRI 9.7B
- EXEL 9.8B
- IPO Year
- PRI N/A
- EXEL 2000
- Fundamental
- Price
- PRI $272.32
- EXEL $36.50
- Analyst Decision
- PRI Buy
- EXEL Buy
- Analyst Count
- PRI 7
- EXEL 18
- Target Price
- PRI $309.14
- EXEL $37.59
- AVG Volume (30 Days)
- PRI 154.9K
- EXEL 2.3M
- Earning Date
- PRI 05-07-2025
- EXEL 05-13-2025
- Dividend Yield
- PRI 1.35%
- EXEL N/A
- EPS Growth
- PRI N/A
- EXEL 170.77
- EPS
- PRI 14.79
- EXEL 1.76
- Revenue
- PRI $3,220,688,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- PRI $2.26
- EXEL $5.78
- Revenue Next Year
- PRI $4.96
- EXEL $10.94
- P/E Ratio
- PRI $18.03
- EXEL $20.74
- Revenue Growth
- PRI 9.80
- EXEL 18.50
- 52 Week Low
- PRI $217.56
- EXEL $20.14
- 52 Week High
- PRI $307.91
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- PRI 56.53
- EXEL 45.67
- Support Level
- PRI $261.05
- EXEL $35.34
- Resistance Level
- PRI $266.75
- EXEL $40.26
- Average True Range (ATR)
- PRI 6.66
- EXEL 1.21
- MACD
- PRI 2.18
- EXEL -0.09
- Stochastic Oscillator
- PRI 77.81
- EXEL 29.79
About PRI Primerica Inc.
Primerica Inc is a provider of financial services to middle-income households in the United States and Canada. The company offers life insurance, mutual funds, annuities, and other financial products, distributed on behalf of third parties. Primerica has three main subsidiaries: Primerica Financial Services, a marketing company; Primerica Life Insurance Company, a principal life insurance underwriting entity; and PFS Investments, which offers investment and savings products, brokerage services, and registered investment advisory. It has four segments Term Life Insurance; Investment and Savings Products; Senior Health; and Corporate and Other Distributed Products. Geogriphically, it derives a majority of its revenue from the US.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.